Pronostic value of biological findings in acute myeloid leukemia

The prognosis between subgroups of patients with acute myeloid leukaemia (AML) may range considerably. Haematological, genetic and clinical analysis has provided possibilities for defining the heterogeneity of prognosis. This furnishes clinically relevant insights into the probability of treatment response and survival in individual cases of AML and it provides a lead in treatment management.